Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Astragaloside Ⅳ (AS-Ⅳ) improved the motor behavior of PD mouse but the alteration of imaging in the PD mice brain was unclear. PD models were established by unilateral injection of ROT into the substantia nigra pars compacta (SNc) of mice. AS-Ⅳ (4 mg/kg) was intraperitoneally injected once a day for 14 days. The pole test and rotarod test were performed to evaluate the alteration of behavior at 32 weeks. The flow cytometry, electrophysiological recordings and MRI were used to assess the neuroprotective effects of AS-IV. AS-Ⅳ ameliorated the motor deficits and reduced the incidence of dystonia in PD animal models. AS-Ⅳ administration inhibited the activation of CD4 T cells and increased the percentage of dopaminergic neurons of burst firing. Meanwhile, AS-Ⅳ altered the brain tissue microstructure and T values in SN. AS-Ⅳ improved motor impairments and efficiently performed a neuroprotective function in ROT-induced mouse model.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neuroscience.2024.12.046 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!